ReviewClinical and molecular allergy : CMA2015
Biomarkers and severe asthma: a critical appraisal.
Review in Clinical and molecular allergy : CMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Biomonitoring Environmental Exposure in Syrian Refugees in Lebanon.Epidemiologia (Basel, Switzerland) · 2024Article
- New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.Clinical science (London, England : 1979) · 2023Review
- Serum Periostin Level in Children with Asthma.Indian journal of pediatrics · 2023Article
- The Role of Systems Biology in Deciphering Asthma Heterogeneity.Life (Basel, Switzerland) · 2022Review
- Identification of Hub Genes and Potential Biomarkers for Childhood Asthma by Utilizing an Established Bioinformatic Analysis Approach.Biomedicines · 2022Article
- Review
- Diagnosis ofBiomedicines · 2022Review
- Allergic Asthma in the Era of Personalized Medicine.Journal of personalized medicine · 2022Review
- Identification of key genes and pathways between mild-moderate and severe asthmatics via bioinformatics analysis.Scientific reports · 2022Article
- Critical evaluation of asthma biomarkers in clinical practice.Frontiers in medicine · 2022Review
- Immunogenicity of a novel anti-allergic vaccine based on house dust mite purified allergens and a combination adjuvant in a murine prophylactic model.Frontiers in allergy · 2022Article
- Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a reliable biomarker for asthma control.Scientific reports · 2021Article
- Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies.Allergy, asthma & immunology research · 2021Review
- Allergic Endotypes and Phenotypes of Asthma.The journal of allergy and clinical immunology. In practice · 2020Article
- Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma.Frontiers in medicine · 2020Article
- Plasma Galectin-3 and urine proteomics predict FEVThe World Allergy Organization journal · 2020Article
- Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology.Molecular aspects of medicine · 2019Review
- Expression of DACT1 in children with asthma and its regulation mechanism.Experimental and therapeutic medicine · 2018Article
- Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease.Journal of asthma and allergy · 2018Review
- Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5-10 % of asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor quality of life. In this review, we describe the biomarkers actually known in scientific literature and used in clinical practice for SA assessment and management: neutrophils, eosinophils, periostin, fractional exhaled nitric oxide, exhaled breath condensate and galectins. Moreover, we give an overview on clinical and biological features characterizing severe asthma, paying special attention to the potential use of these ones as reliable markers. We finally underline the need to define different biomarkers panels to select patients affected by severe asthma for specific and personalized therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.